Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLINI: Venetoclax + Bortezomib + Dexamethasone in RRMM
NCT02755597Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2016
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of venetoclax in multiple myeloma (MM), sponsored by AbbVie Inc.. Started Jul 2016; status: completed.
02
Drugs
venetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02755597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02755597.